Study: Eli Lilly COVID-19 Drug Combo Found Effective, Cuts Hospitalizations, Deaths By 87%:

The findings further support dosing already authorized by the FDA, Lilly said


A combination of two Eli Lilly antibody drugs cut the risk of COVID-19-related hospitalizations and deaths by 87%, the company announced Wednesday, further upholding dosing already authorized by the Food and Drug Administration.

The findings draw from a BLAZE-1 Phase 3 cohort with 769 mild-to-moderate coronavirus patients aged 12 and up at high-risk of progressing to severe disease. There were 15 “events” like hospitalizations or deaths in the placebo group, and four “events” in a group of patients taking 700 mg of bamlanivimab and 1400 mg of etesevimab together, “representing an 87 percent risk reduction,” Lilly announced.

The company noted four deaths, which were all associated with COVID-19 and all occurred in the placebo group. Lilly said the new findings were consistent with other data previously announced, like a cohort involving high-risk patients given 2800 mg of bamlanivimab and 2800 mg of etesevimab, resulting in a 70% reduction in risk of hospitalization and death.

Read More

Leave a Reply


ACLU Editor Tweets Then Deletes Message Saying She Is ‘Angry’ A Republican Senator Survived Covid-19

Shocking: French Schoolgirl Admits Lying About Muslim ‘Muhammad Cartoon’ That Led To Teachers Beheading